Regeneron Stock Plummets After Earnings Miss -- Barrons.com

Dow Jones

Apr 29

By Elsa Ohlen

Regeneron Pharmaceuticals stock fell sharply after the company's latest earnings came in below Wall Street's expectations Tuesday.

First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet.

Shares fell 9.4% to $553.73 in early trading.

"The magnitude of the miss was clearly greater than expected," Cantor Fitzgerald analyst Carter Gould said. However, he noted the miss was partially offset by sales of its high-dose eye drug Eylea coming in better than some had feared. Sales of the medicine were $307 million in the quarter; the expectation was $328 million.

Total Eylea sales fell 26% compared with a year ago -- to $1.04 billion.

The company reiterated its earnings guidance for this year but lowered its margin expectations on net product sales and capital expenditure slightly.

Write to Elsa Ohlen at elsa.ohlen@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

April 29, 2025 10:29 ET (14:29 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2531267756"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531267756\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531267756?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531267756","market":"sh","top_or_hot":-1,"title":"Regeneron Stock Plummets After Earnings Miss -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elsa Ohlen \n</p>\n<p>\n  Regeneron Pharmaceuticals stock fell sharply after the company's latest earnings came in below Wall Street's expectations Tuesday. \n</p>\n<p>\n     First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet. \n</p>\n<p>\n     Shares fell 9.4% to $553.73 in early trading. \n</p>\n<p>\n     \"The magnitude of the miss was clearly greater than expected,\" Cantor Fitzgerald analyst Carter Gould said. However, he noted the miss was partially offset by sales of its high-dose eye drug Eylea coming in better than some had feared. Sales of the medicine were $307 million in the quarter; the expectation was $328 million. \n</p>\n<p>\n     Total Eylea sales fell 26% compared with a year ago -- to $1.04 billion. \n</p>\n<p>\n     The company reiterated its earnings guidance for this year but lowered its margin expectations on net product sales and capital expenditure slightly. \n</p>\n<p>\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 10:29 ET (14:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Stock Plummets After Earnings Miss -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Stock Plummets After Earnings Miss -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-29 22:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elsa Ohlen \n</p>\n<p>\n  Regeneron Pharmaceuticals stock fell sharply after the company's latest earnings came in below Wall Street's expectations Tuesday. \n</p>\n<p>\n     First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet. \n</p>\n<p>\n     Shares fell 9.4% to $553.73 in early trading. \n</p>\n<p>\n     \"The magnitude of the miss was clearly greater than expected,\" Cantor Fitzgerald analyst Carter Gould said. However, he noted the miss was partially offset by sales of its high-dose eye drug Eylea coming in better than some had feared. Sales of the medicine were $307 million in the quarter; the expectation was $328 million. \n</p>\n<p>\n     Total Eylea sales fell 26% compared with a year ago -- to $1.04 billion. \n</p>\n<p>\n     The company reiterated its earnings guidance for this year but lowered its margin expectations on net product sales and capital expenditure slightly. \n</p>\n<p>\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 10:29 ET (14:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2531267756","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531267756","pubTimestamp":1745936940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Regeneron Pharmaceuticals stock fell sharply after the company's latest earnings came in below Wall Street's expectations Tuesday.First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet.Shares fell 9.4% to $553.73 in early trading.\"The magnitude of the miss was clearly greater than expected,\" Cantor Fitzgerald analyst Carter Gould said. However, he noted the miss was partially offset by sales of its high-dose eye drug Eylea coming in better than some had feared. Sales of the medicine were $307 million in the quarter; the expectation was $328 million.Total Eylea sales fell 26% compared with a year ago -- to $1.04 billion.The company reiterated its earnings guidance for this year but lowered its margin expectations on net product sales and capital expenditure slightly.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published indepen","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"再生元股价因盈利未达预期而暴跌--Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"By Elsa Ohlen \n\n\n  Regeneron Pharmaceuticals stock fell sharply after the company's latest earnings came in below Wall Street's expectations Tuesday. \n\n\n     First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet. \n\n\n     Shares fell 9.4% to $553.73 in early trading. \n\n\n     \"The magnitude of the miss was clearly greater than expected,\" Cantor Fitzgerald analyst Carter Gould said. However, he noted the miss was partially offset by sales of its high-dose eye drug Eylea coming in better than some had feared. Sales of the medicine were $307 million in the quarter; the expectation was $328 million. \n\n\n     Total Eylea sales fell 26% compared with a year ago -- to $1.04 billion. \n\n\n     The company reiterated its earnings guidance for this year but lowered its margin expectations on net product sales and capital expenditure slightly. \n\n\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n\n\n     This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 10:29 ET (14:29 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}